| scholarly article | Q13442814 |
| P356 | DOI | 10.3109/08830185.2012.680552 |
| P698 | PubMed publication ID | 22587022 |
| P2093 | author name string | Santiago Dueñas-Carrera | |
| Liz Alvarez-Lajonchere | |||
| P2860 | cites work | Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children | Q43035295 |
| Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. | Q43035496 | ||
| Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: correlation with clinical disease stages | Q43036009 | ||
| Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity | Q43036305 | ||
| A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C. | Q43038008 | ||
| Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients. | Q43039843 | ||
| Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy | Q43040590 | ||
| Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. | Q43046782 | ||
| Animal models for hepatitis C and related liver disease | Q43161781 | ||
| Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-class I-A alleles | Q45382800 | ||
| Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. | Q45418238 | ||
| Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee | Q45422073 | ||
| Characterization of liver histopathology in a transgenic mouse model expressing genotype 1a hepatitis C virus core and envelope proteins 1 and 2. | Q45435048 | ||
| CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained | Q45740431 | ||
| Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers | Q46107112 | ||
| Immunization with a DNA vaccine candidate in chronic hepatitis C patients is safe, well tolerated and does not impair immune response induction after anti-hepatitis B vaccination. | Q50561429 | ||
| Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C. | Q50562489 | ||
| Molecular signature of CD8+ T cell exhaustion during chronic viral infection. | Q51970485 | ||
| HLA DR13 and HCV vertical infection | Q57005698 | ||
| Vaccination for hepatitis C virus: closing in on an evasive target | Q22305922 | ||
| Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees | Q24685256 | ||
| Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection | Q27469507 | ||
| Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease | Q27473001 | ||
| Isolation and functional analysis of circulating dendritic cells from hepatitis C virus (HCV) RNA-positive and HCV RNA-negative patients with chronic hepatitis C: role of antiviral therapy | Q27478115 | ||
| Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C | Q27478257 | ||
| Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma | Q27478384 | ||
| Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection | Q27485119 | ||
| Increased Cytotoxic T-Lymphocyte Epitope Variant Cross-Recognition and Functional Avidity Are Associated with Hepatitis C Virus Clearance | Q27485452 | ||
| High Level of PD-1 Expression on Hepatitis C Virus (HCV)-Specific CD8+ and CD4+ T Cells during Acute HCV Infection, Irrespective of Clinical Outcome | Q27485454 | ||
| Stable Cytotoxic T Cell Escape Mutation in Hepatitis C Virus Is Linked to Maintenance of Viral Fitness | Q27486654 | ||
| Previously Infected Chimpanzees Are Not Consistently Protected against Reinfection or Persistent Infection after Reexposure to the Identical Hepatitis C Virus Strain | Q27486778 | ||
| Hepatic Transcriptome Analysis of Hepatitis C Virus Infection in Chimpanzees Defines Unique Gene Expression Patterns Associated with Viral Clearance | Q27487011 | ||
| Evidence for Protection against Chronic Hepatitis C Virus Infection in Chimpanzees by Immunization with Replicating Recombinant Vaccinia Virus | Q27487131 | ||
| Hepatitis C Virus (HCV)–Specific Immune Responses of Long‐Term Injection Drug Users Frequently Exposed to HCV | Q27488816 | ||
| High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection | Q27490345 | ||
| Pathogenesis of Hepatitis C Virus Infection in Tupaia belangeri | Q27490544 | ||
| Selection-driven immune escape is not a significant factor in the failure of CD4 T cell responses in persistent hepatitis C virus infection | Q27490924 | ||
| Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance | Q28255243 | ||
| Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines | Q28260203 | ||
| Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study | Q28269827 | ||
| IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection | Q28276247 | ||
| IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy | Q29614896 | ||
| The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide | Q29616215 | ||
| Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C | Q29619541 | ||
| Diagnosis, management, and treatment of hepatitis C: an update | Q29619682 | ||
| Adaptive immune responses in acute and chronic hepatitis C virus infection | Q29619722 | ||
| Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection | Q29620141 | ||
| Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C | Q29620614 | ||
| Hepatitis C virus replication in mice with chimeric human livers | Q29620650 | ||
| HCV Persistence and Immune Evasion in the Absence of Memory T Cell Help | Q29620766 | ||
| Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response | Q29620891 | ||
| Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C. | Q30767073 | ||
| Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection | Q33929089 | ||
| Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus | Q33955998 | ||
| The natural history of hepatitis C virus infection: host, viral, and environmental factors | Q33974693 | ||
| Ribavirin improves early responses to peginterferon through improved interferon signaling | Q33987120 | ||
| Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. | Q34072573 | ||
| A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals | Q34091925 | ||
| Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. | Q34097560 | ||
| Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia | Q34158520 | ||
| Pathogenesis of Hepatitis E Virus and Hepatitis C Virus in Chimpanzees: Similarities and Differences | Q34190622 | ||
| Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro | Q34259130 | ||
| Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users | Q34381567 | ||
| Immune responses and immunity in hepatitis C virus infection | Q34484607 | ||
| Evidence for human leukocyte antigen heterozygote advantage against hepatitis C virus infection | Q34700869 | ||
| A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. | Q34733367 | ||
| Tupaia CD81, SR-BI, claudin-1, and occludin support hepatitis C virus infection | Q34742966 | ||
| Characterization of natural killer cells in tamarins: a technical basis for studies of innate immunity | Q35038257 | ||
| Interferon lambdas: the next cytokine storm | Q35154826 | ||
| A genetically humanized mouse model for hepatitis C virus infection | Q35174543 | ||
| Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees | Q35249069 | ||
| Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C | Q35508148 | ||
| Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. | Q35964254 | ||
| Neutralizing antibody response during acute and chronic hepatitis C virus infection | Q35971609 | ||
| Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice | Q36115197 | ||
| Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies | Q36346436 | ||
| A target on the move: innate and adaptive immune escape strategies of hepatitis C virus | Q36368645 | ||
| Design of therapeutic vaccines: hepatitis B as an example | Q37274697 | ||
| Decreased IP-10 and elevated TGFbeta1 levels are associated with viral clearance following therapy in patients with hepatitis C virus | Q37324174 | ||
| Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. | Q37381208 | ||
| DNA vaccine therapy for chronic hepatitis C virus (HCV) infection: immune control of a moving target. | Q37519635 | ||
| Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients | Q37596619 | ||
| Genetic factors in mother-to-child transmission of HCV infection | Q38353652 | ||
| Hepatitis C virus with a naturally occurring single amino-acid substitution in the E2 envelope protein escapes neutralization by naturally-induced and vaccine-induced antibodies | Q39708765 | ||
| Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. | Q39723501 | ||
| Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. | Q39866377 | ||
| Chimeric GB virus B genomes containing hepatitis C virus p7 are infectious in vivo | Q39930810 | ||
| Selection of high-avidity CD8 T cells correlates with control of hepatitis C virus infection | Q39949329 | ||
| Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo | Q40178086 | ||
| Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. | Q40209502 | ||
| Assembly of functional hepatitis C virus glycoproteins on infectious pseudoparticles occurs intracellularly and requires concomitant incorporation of E1 and E2 glycoproteins. | Q40349326 | ||
| Effect of IL-4 and IL-13 on collagen production in cultured LI90 human hepatic stellate cells | Q40444779 | ||
| Direct enumeration and functional assessment of circulating dendritic cells in patients with liver disease. | Q40515590 | ||
| A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. | Q40547706 | ||
| Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus | Q40588817 | ||
| Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection | Q40836214 | ||
| Clearance of genotype 1b hepatitis C virus in chimpanzees in the presence of vaccine-induced E1-neutralizing antibodies | Q42869198 | ||
| Cutting edge: programmed death-1 expression is increased on immunocytes in chronic hepatitis C virus and predicts failure of response to antiviral therapy: race-dependent differences | Q42977043 | ||
| Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. | Q42978347 | ||
| Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion. | Q42980990 | ||
| Hepatitis C virus (HCV)--specific T cell responses in injection drug users with apparent resistance to HCV infection | Q42982614 | ||
| Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial | Q42983179 | ||
| Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort | Q42984783 | ||
| Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source | Q42986139 | ||
| Early viraemia clearance during antiviral therapy of chronic hepatitis C improves dendritic cell functions | Q42986359 | ||
| T-cell vaccines that elicit effective immune responses against HCV in chimpanzees may create greater immune pressure for viral mutation | Q42987508 | ||
| Clearance of hepatitis C in chimpanzees is associated with intrahepatic T-cell perforin expression during the late acute phase | Q42990385 | ||
| Analyses of amino acid sequences in hypervariable region-1 of hepatitis C virus (HCV) in sera from chimpanzees infected three times with the same HCV strain | Q42991625 | ||
| Protection against chronic hepatitis C virus infection after rechallenge with homologous, but not heterologous, genotypes in a chimpanzee model. | Q42996019 | ||
| A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees | Q42998134 | ||
| Antibodies against hepatitis C virus-like particles and viral clearance in acute and chronic hepatitis C. | Q42999959 | ||
| Hierarchy of baby-linked immunogenetic risk factors in the vertical transmission of hepatitis C virus | Q43001200 | ||
| CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus | Q43030984 | ||
| Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-alpha and plasmacytoid dendritic cell loss in chronic HCV infection. | Q43033205 | ||
| P433 | issue | 3 | |
| P921 | main subject | immunology | Q101929 |
| hepatitis C | Q154869 | ||
| Hepatitis C virus | Q708693 | ||
| P304 | page(s) | 223-242 | |
| P577 | publication date | 2012-06-01 | |
| P1433 | published in | International Reviews of Immunology | Q6052764 |
| P1476 | title | Complete definition of immunological correlates of protection and clearance of hepatitis C virus infection: a relevant pending task for vaccine development | |
| P478 | volume | 31 |
| Q35861251 | A Multiantigenic DNA Vaccine That Induces Broad Hepatitis C Virus-Specific T-Cell Responses in Mice |
| Q42234870 | A chimeric protein encompassing hepatitis C virus epitopes is able to elicit both humoral and cell-mediated immune responses in mice |
| Q38844555 | Intradermal delivery of DNA encoding HCV NS3 and perforin elicits robust cell-mediated immunity in mice and pigs. |
| Q42239683 | Neutralizing antibodies and broad, functional T cell immune response following immunization with hepatitis C virus proteins-based vaccine formulation |
| Q37505405 | Prospects for prophylactic hepatitis C vaccines based on virus-like particles |
| Q89522583 | Protective cellular immune response against hepatitis C virus elicited by chimeric protein formulations in BALB/c mice |
| Q38081966 | Virus-like particle-based vaccines against hepatitis C virus infection. |
Search more.